{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":24,"n_cols":5,"rows_kept":24,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[4,2,4,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[8,2,8,3],[11,2,11,3],[12,2,12,3],[16,2,16,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910811415603321"]
[null,null,"Titolo",null,"Advances in cancer research . Volume 125 ABC transporters and cancer / / edited by John D. Schuetz, Toshihisa Ishikawa ; contributors Suresh V. Ambudkar [and thirty one others]"]
[null,null,"Pubbl/distr/stampa",null,"London, England : , : Academic Press, , 2015"]
[{"$nulls":4},"©2015"]
[null,null,"ISBN",null,"0-12-801361-3"]
[null,null,"Edizione",null,"[First edition.]"]
[null,null,"Descrizione fisica",null,"1 online resource (280 p.)"]
[null,null,"Disciplina",null,"616.9940072"]
[null,null,"Soggetti",null,"Cancer - Research"]
[{"$nulls":4},"Drug resistance in cancer cells"]
[{"$nulls":4},"Cancer - Chemotherapy"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references at the end of each chapters and index."]
[null,null,"Nota di contenuto",null,"Front Cover; ABC Transporters and Cancer; Copyright; Dedication; Contents; Contributors; Preface; Chapter 1: Apical ABC Transporters and Cancer Chemotherapeutic Drug Disposition; 1. Introduction to Apical ABC Transporters; 2. Impact of Apical ABC Transporters on Intestinal Absorption of Oral Chemotherapeutic Drugs; 2.1. Apical ABC transporters affecting the oral bioavailability of taxanes; 2.1.1. ABCB1 and oral taxane availability; 2.1.2. ABCC2 and oral taxane availability; 2.1.3. ABCB1 inhibitors to improve taxane oral availability"]
[{"$nulls":4},"2.1.4. Assessing CNS toxicity risks of using ABCB1 inhibitors to improve oral taxane availability2.1.5. Possible effects of ABCB1 inhibitors on enhancing taxane antitumor efficacy; 2.2. Apical ABC transporters in the oral bioavailability of rationally designed anticancer drugs; 2.2.1. Tyrosine kinase inhibitors; 2.2.2. PARP inhibitors; 2.2.3. Chemical inhibition of transporters to increase oral availability of rationally designed anticancer drugs; 2.2.4. Importance of the sensitivity and specificity of in vitro assays used to assess ABC transporter substrates"]
[{"$nulls":4},"3. Impact of Apical ABC Transporters on Brain Disposition of Oral Chemotherapeutic Drugs3.1. Does the BBB matter in drug delivery to brain tumors?; 3.2. Apical efflux transporters in the BBB affecting brain accumulation of anticancer drugs; 3.2.1. Drugs affected mostly by Abcb1a but also by Abcg2 in their brain accumulation; 3.2.2. Drugs "]
[{"$nulls":4},"only affected by Abcb1a in their brain accumulation; 3.2.3. Drugs affected mostly by Abcg2 but also by Abcb1a in their brain accumulation; 3.2.4. Three different apical BBB ABC efflux transporters affect brain accumulation of some camptothecins"]
[{"$nulls":4},"3.2.5. Models to explain the disproportionate effect of combined deficiency of Abcb1 and Abcg2 on brain accumulation of s...3.2.6. Why are many rationally designed anticancer drugs still ABCB1 and/or ABCG2 substrates?; 3.2.7. Limitations of knockout mouse models to study ABC transporter functions at the BBB; 3.2.8. Tissue and cellular context may affect the in vivo impact of apical ABC efflux transporters; 3.2.9. Use of chemical inhibitors to enhance brain accumulation of ABC transporter substrate drugs; 4. Concluding Remarks; References"]
[{"$nulls":4},"Chapter 2: Regulation of ABC Transporters Blood-Brain Barrier: The Good, the Bad, and the Ugly1. Introduction; 2. Blood-Brain Barriers; 2.1. Assessing blood-brain barrier function; 3. ABC Transporters at the Blood-Brain Barrier; 4. The Bad and the Ugly: Mechanisms that Increase Transporter Expression and Reduce Drug Delivery to the CNS; 4.1. Xenobiotic-activated transcription factors; 4.2. Stress-activated transcription factors; 4.3. Disease; 5. The Good: Mechanisms that Reduce Transporter Activity/Expression and Have the Potential to Improve Drug Delivery to th...; 5.1. P-glycoprotein"]
[{"$nulls":4},"5.2. BCRP"]
[null,null,null,"Sommario/riassunto","<i>  ABC Transporters and Cancer</i> provides invaluable information on the exciting and fast-moving field of cancer research. Here, outstanding and original reviews are presented on a variety of topics. This volume covers ABC transporters and cancer, and is suitable for researchers and students alike. <br><br><ul><li>Provides information on cancer research</li><li>Outstanding and original reviews</li><li>Suitable for researchers and students</li></ul>"]